Do analysts prefer INBX or AVIR?

Inhibrx Biosciences presently has a consensus target price of $150.00, suggesting a potential upside of 58.31%. Given Inhibrx Biosciences' higher possible upside, research analysts plainly believe Inhibrx Biosciences is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx Biosciences 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.33 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is INBX or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -72.32% Atea Pharmaceuticals N/A -57.01% -51.49%

Does the media favor INBX or AVIR?

In the previous week, Inhibrx Biosciences had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Inhibrx Biosciences and 2 mentions for Atea Pharmaceuticals. Inhibrx Biosciences' average media sentiment score of 0.51 beat Atea Pharmaceuticals' score of 0.47 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AVIR or COAG?

Hemab Therapeutics has a consensus target price of $41.40, indicating a potential upside of 12.71%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Hemab Therapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Hemab Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83

Which has higher earnings & valuation, AVIR or COAG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A Hemab Therapeutics N/A N/A N/A N/A N/A

Is AVIR or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% Hemab Therapeutics N/A N/A N/A

Does the media favor AVIR or COAG?

In the previous week, Hemab Therapeutics had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Hemab Therapeutics and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.47 beat Hemab Therapeutics' score of 0.38 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MRVI or AVIR?

Maravai LifeSciences currently has a consensus price target of $5.50, indicating a potential downside of 11.86%. Given Maravai LifeSciences' higher possible upside, research analysts plainly believe Maravai LifeSciences is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media prefer MRVI or AVIR?

In the previous week, Maravai LifeSciences had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Maravai LifeSciences and 2 mentions for Atea Pharmaceuticals. Maravai LifeSciences' average media sentiment score of 0.62 beat Atea Pharmaceuticals' score of 0.47 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AVIR or PURR?

Hyperliquid Strategies has a consensus target price of $9.25, indicating a potential upside of 17.53%. Given Hyperliquid Strategies' higher probable upside, analysts clearly believe Hyperliquid Strategies is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Hyperliquid Strategies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is AVIR or PURR more profitable?

Hyperliquid Strategies' return on equity of -56.04% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% Hyperliquid Strategies N/A -56.04% -52.22%

Does the media favor AVIR or PURR?

In the previous week, Hyperliquid Strategies had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Hyperliquid Strategies and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.47 beat Hyperliquid Strategies' score of 0.30 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperliquid Strategies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AKTS or AVIR?

Aktis Oncology presently has a consensus target price of $34.00, indicating a potential upside of 5.07%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Aktis Oncology is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aktis Oncology 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher earnings and valuation, AKTS or AVIR?

Aktis Oncology has higher revenue and earnings than Atea Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $8.28M 208.79 -$63.73M N/A N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A

Is AKTS or AVIR more profitable?

Aktis Oncology's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Atea Pharmaceuticals N/A -57.01% -51.49%

Does the media favor AKTS or AVIR?

In the previous week, Aktis Oncology had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Aktis Oncology and 2 mentions for Atea Pharmaceuticals. Aktis Oncology's average media sentiment score of 0.62 beat Atea Pharmaceuticals' score of 0.47 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Atea Pharmaceuticals (AVIR) Competitors

$4.65 +0.04 (+0.87%)

Closing price 04:00 PM Eastern

Extended Trading

$4.57 -0.08 (-1.81%)

As of 04:38 PM Eastern

Compare

AVIR vs. INBX, COAG, MRVI, PURR, and AKTS

Should you buy Atea Pharmaceuticals stock or one of its competitors? MarketBeat compares Atea Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atea Pharmaceuticals include Inhibrx Biosciences (INBX), Hemab Therapeutics (COAG), Maravai LifeSciences (MRVI), Hyperliquid Strategies (PURR), and Aktis Oncology (AKTS). These companies are all part of the "pharmaceutical products" industry.

How does Atea Pharmaceuticals compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, Inhibrx Biosciences had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Inhibrx Biosciences and 2 mentions for Atea Pharmaceuticals. Inhibrx Biosciences' average media sentiment score of 0.51 beat Atea Pharmaceuticals' score of 0.47 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inhibrx Biosciences presently has a consensus target price of $150.00, suggesting a potential upside of 58.31%. Given Inhibrx Biosciences' higher possible upside, research analysts plainly believe Inhibrx Biosciences is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Atea Pharmaceuticals' return on equity of -57.01% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Inhibrx Biosciences has a beta of 3.33, indicating that its share price is 233% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Inhibrx Biosciences has higher revenue and earnings than Atea Pharmaceuticals. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,069.22	-$140.05M	-$8.39	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Inhibrx Biosciences and Atea Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Hemab Therapeutics?

Atea Pharmaceuticals (NASDAQ:AVIR) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

In the previous week, Hemab Therapeutics had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Hemab Therapeutics and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.47 beat Hemab Therapeutics' score of 0.38 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemab Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Hemab Therapeutics	N/A	N/A	N/A

Hemab Therapeutics has a consensus target price of $41.40, indicating a potential upside of 12.71%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Hemab Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Hemab Therapeutics beats Atea Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Maravai LifeSciences currently has a consensus price target of $5.50, indicating a potential downside of 11.86%. Given Maravai LifeSciences' higher possible upside, research analysts plainly believe Maravai LifeSciences is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Maravai LifeSciences has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

In the previous week, Maravai LifeSciences had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Maravai LifeSciences and 2 mentions for Atea Pharmaceuticals. Maravai LifeSciences' average media sentiment score of 0.62 beat Atea Pharmaceuticals' score of 0.47 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atea Pharmaceuticals has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Maravai LifeSciences has higher revenue and earnings than Atea Pharmaceuticals. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$204.73M	7.87	-$130.77M	-$0.71	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Summary

Maravai LifeSciences beats Atea Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Hyperliquid Strategies?

Atea Pharmaceuticals (NASDAQ:AVIR) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Hyperliquid Strategies had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Hyperliquid Strategies and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.47 beat Hyperliquid Strategies' score of 0.30 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperliquid Strategies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 9.4% of Hyperliquid Strategies shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Hyperliquid Strategies has a consensus target price of $9.25, indicating a potential upside of 17.53%. Given Hyperliquid Strategies' higher probable upside, analysts clearly believe Hyperliquid Strategies is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hyperliquid Strategies' return on equity of -56.04% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Atea Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market.

Hyperliquid Strategies has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Hyperliquid Strategies	$1M	1,136.81	-$16.01M	-$7.37	N/A

Summary

Hyperliquid Strategies beats Atea Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

In the previous week, Aktis Oncology had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Aktis Oncology and 2 mentions for Atea Pharmaceuticals. Aktis Oncology's average media sentiment score of 0.62 beat Atea Pharmaceuticals' score of 0.47 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aktis Oncology has higher revenue and earnings than Atea Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$8.28M	208.79	-$63.73M	N/A	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Aktis Oncology's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Aktis Oncology presently has a consensus target price of $34.00, indicating a potential upside of 5.07%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Aktis Oncology is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Aktis Oncology beats Atea Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

Get Atea Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVIR vs. The Competition

Export

Metric	Atea Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$372.13M	$3.64B	$6.77B	$12.61B
Dividend Yield	N/A	2.21%	2.66%	6.21%
P/E Ratio	-2.20	21.26	27.34	24.90
Price / Sales	N/A	334.72	560.01	115.85
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	1.32	8.75	11.00	6.57
Net Income	-$158.35M	$23.81M	$3.57B	$336.70M
7 Day Performance	3.79%	3.63%	2.54%	3.34%
1 Month Performance	-0.43%	1.62%	0.88%	1.71%
1 Year Performance	29.17%	69.41%	36.79%	32.01%

Atea Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVIR Atea Pharmaceuticals	1.0082 of 5 stars	$4.65 +0.9%	N/A	+33.6%	$372.13M	N/A	N/A	70
INBX Inhibrx Biosciences	2.4831 of 5 stars	$92.91 -0.4%	$150.00 +61.4%	+561.8%	$1.37B	$1.30M	N/A	166	Analyst Downgrade
COAG Hemab Therapeutics	3.9111 of 5 stars	$29.15 -8.2%	$41.40 +42.0%	N/A	$1.36B	N/A	N/A	72
MRVI Maravai LifeSciences	1.6667 of 5 stars	$5.37 +2.3%	$5.50 +2.4%	+158.7%	$1.36B	$185.74M	N/A	610	Positive News
PURR Hyperliquid Strategies	2.1455 of 5 stars	$8.14 -11.5%	$9.25 +13.6%	N/A	$1.33B	$1M	N/A	N/A	Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVIR) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. INBX, COAG, MRVI, PURR, and AKTS

How does Atea Pharmaceuticals compare to Inhibrx Biosciences?

Summary

How does Atea Pharmaceuticals compare to Hemab Therapeutics?

Summary

How does Atea Pharmaceuticals compare to Maravai LifeSciences?

Summary

How does Atea Pharmaceuticals compare to Hyperliquid Strategies?

Summary

How does Atea Pharmaceuticals compare to Aktis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. INBX, COAG, MRVI, PURR, and AKTS

How does Atea Pharmaceuticals compare to Inhibrx Biosciences?

Does the media favor INBX or AVIR?

Do analysts prefer INBX or AVIR?

Is INBX or AVIR more profitable?

Which has more volatility & risk, INBX or AVIR?

Which has stronger earnings and valuation, INBX or AVIR?

Do insiders and institutionals hold more shares of INBX or AVIR?

Summary

How does Atea Pharmaceuticals compare to Hemab Therapeutics?

Does the media favor AVIR or COAG?

Is AVIR or COAG more profitable?

Do analysts recommend AVIR or COAG?

Do institutionals and insiders believe in AVIR or COAG?

Which has higher earnings & valuation, AVIR or COAG?

Summary

How does Atea Pharmaceuticals compare to Maravai LifeSciences?

Do analysts rate MRVI or AVIR?

Do institutionals & insiders hold more shares of MRVI or AVIR?

Which has more volatility & risk, MRVI or AVIR?

Does the media prefer MRVI or AVIR?

Is MRVI or AVIR more profitable?

Which has better earnings and valuation, MRVI or AVIR?

Summary

How does Atea Pharmaceuticals compare to Hyperliquid Strategies?

Does the media favor AVIR or PURR?

Do insiders & institutionals believe in AVIR or PURR?

Do analysts recommend AVIR or PURR?

Is AVIR or PURR more profitable?

Which has more risk & volatility, AVIR or PURR?

Which has preferable earnings and valuation, AVIR or PURR?

Summary

How does Atea Pharmaceuticals compare to Aktis Oncology?

Does the media favor AKTS or AVIR?

Do insiders and institutionals hold more shares of AKTS or AVIR?

Which has higher earnings and valuation, AKTS or AVIR?

Is AKTS or AVIR more profitable?

Do analysts prefer AKTS or AVIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools